Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Direct immunofluorescence

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44294   clinical trials with a EudraCT protocol, of which   7351   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    20 result(s) found for: Direct immunofluorescence. Displaying page 1 of 1.
    EudraCT Number: 2020-000287-32 Sponsor Protocol Number: D325AC00002 Start Date*: 2020-12-02
    Sponsor Name:AstraZeneca AB
    Full Title: A Multinational, Randomized, Double-blind, Parallel-group, Placebo-controlled Study to Investigate the Use of Benralizumab as a Treatment Option for Patients with Bullous Pemphigoid (FJORD)
    Medical condition: Bullous Pemphigoid
    Disease: Version SOC Term Classification Code Term Level
    21.1 10040785 - Skin and subcutaneous tissue disorders 10006567 Bullous pemphigoid LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BG (Prematurely Ended) DE (Prematurely Ended) FR (Completed) IT (Prematurely Ended) GR (Completed)
    Trial results: View results
    EudraCT Number: 2005-002391-14 Sponsor Protocol Number: SAWV1003 Start Date*: 2005-09-29
    Sponsor Name:Moorfields Eye Hospital NHS Foundation Trust
    Full Title: Pulsed Intravenous Methylprednisolone for Ocular Pemphigoid- A Pilot Study
    Medical condition: ocular mucous membrane pemphigoid
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2020-005987-67 Sponsor Protocol Number: AK802 Start Date*: 2021-12-22
    Sponsor Name:Akari Therapeutics Plc
    Full Title: A randomized, part A partial blinded and part B double blinded, placebo-controlled 24-week clinical study to evaluate the efficacy and safety of nomacopan therapy in adult patients with bullous pem...
    Medical condition: moderate to severe bullous pemphigoid
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004858 10006567 Bullous pemphigoid LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing) NL (Ongoing)
    Trial results: View results
    EudraCT Number: 2011-000756-42 Sponsor Protocol Number: MEX0111 Start Date*: Information not available in EudraCT
    Sponsor Name:Dompé s.p.a.
    Full Title: A phase 2, multicentre, single arm, pilot study to assess the efficacy and the safety of 150 mg twice a day oral DF2156A in patients with active bullous pemphigoid.
    Medical condition: active bullous pemphigoid
    Disease: Version SOC Term Classification Code Term Level
    14.0 10040785 - Skin and subcutaneous tissue disorders 10006567 Bullous pemphigoid LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-002333-40 Sponsor Protocol Number: ARGX-113-1701 Start Date*: 2018-01-31
    Sponsor Name:argenx BVBA
    Full Title: An Open-label, Non-controlled, Phase II Study to Evaluate the Safety, Pharmacodynamics, Pharmacokinetics, Efficacy and Conditions of Use of ARGX-113 in Patients with Mild to Moderate Pemphigus (Vul...
    Medical condition: Pemphigus (Vulgaris or Foliaceus)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10052802 Pemphigus vulgaris LLT
    20.0 100000004858 10057069 Pemphigus foliaceus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) HU (Completed) IT (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2017-002836-18 Sponsor Protocol Number: AK801 Start Date*: 2018-05-07
    Sponsor Name:Akari Therapeutics Plc.
    Full Title: A Phase IIa open label single arm study of safety and efficacy of rVA576 in adult mild to moderate Bullous Pemphigoid subjects
    Medical condition: Mild to Moderate Bullous Pemphigoid
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004858 10006567 Bullous pemphigoid LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2011-004361-32 Sponsor Protocol Number: KKS-166 Start Date*: 2013-02-26
    Sponsor Name:Philipps-Universität Marburg
    Full Title: Effect of simvastatin in combination with a superpotent topical corticosteroid in bullous pemphigoid A prospective multi-centre randomised double-blind placebo-controlled pilot study
    Medical condition: Bullous pemphigoid (BP) is the most frequent blistering autoimmune disease of the skin. The disease itself is characterized by the development of bullous lesions, frequently following a prodromal p...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-001245-41 Sponsor Protocol Number: 2005/Diaminodiphenylsulfon/1 Start Date*: 2005-09-23
    Sponsor Name:Department of Dermatology, Hospital of the Medical University Graz
    Full Title: A single-center, randomized, double-blind, placebo-controlled trial evaluating the efficacy and safety of Dapsone in adult patients with cutaneous leukocytoclastic vasculitis
    Medical condition: Cutaneous leukocytoclastic vasculitis is an inflammatory vascular disease and is manifested clinically by a spectrum of cutaneous lesions, although “papable purpura” is its clinical hallmark. The p...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Ongoing)
    Trial results: View results
    EudraCT Number: 2014-000382-41 Sponsor Protocol Number: WA29330 Start Date*: 2015-03-06
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A randomized, double-blind, double-dummy active-comparator, multicenter study to evaluate the efficacy and safety of rituximab versus MMF in patients with pemphigus vulgaris
    Medical condition: Pemphigus Vulgaris (PV)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10052802 Pemphigus vulgaris LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed) IT (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2013-000211-24 Sponsor Protocol Number: IMAT-PV Start Date*: 2013-10-01
    Sponsor Name:Ruprecht-Karls-University Heidelberg
    Full Title: A multicenter, randomized, placebo-controlled, double-blind proof of concept study to evaluate the efficacy and safety of the human normal immunoglobulin Intratect® 5% for intravenous use as adjuva...
    Medical condition: patients with Pemphigus vulgaris
    Disease: Version SOC Term Classification Code Term Level
    16.0 100000004858 10052802 Pemphigus vulgaris LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-004040-70 Sponsor Protocol Number: BUC-56/PBC Start Date*: 2008-05-15
    Sponsor Name:Dr. Falk Pharma GmbH
    Full Title: Double-blind, randomised, placebo-controlled, multi-centre phase III clinical study comparing the combination of ursodeoxycholic acid capsules plus budesonide capsules to ursodeoxycholic acid capsu...
    Medical condition: PBC patients with an incomplete response to UDCA treatment defined by the failure to achieve s-AP levels < 1.5x upper limit of normal after at least 6 months of treatment with UDCA and with inflamm...
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004871 10036680 Primary biliary cirrhosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) SE (Completed) FR (Completed) AT (Completed) NL (Completed) FI (Completed) ES (Completed) HU (Completed) GB (Completed) LT (Completed) DK (Completed) IT (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2016-002443-42 Sponsor Protocol Number: GS-US-427-4024 Start Date*: 2017-01-09
    Sponsor Name:Gilead Sciences, Inc.
    Full Title: A Phase 2, Randomized, Double-Blind, Placebo Controlled Study Evaluating the Safety, Tolerability, and Efficacy of GS-9674 in Subjects with Primary Biliary Cholangitis Without Cirrhosis
    Medical condition: Primary Biliary Cholangitis
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004871 10036680 Primary biliary cirrhosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2017-003528-62 Sponsor Protocol Number: EDP305-201 Start Date*: 2018-12-05
    Sponsor Name:Enanta Pharmaceuticals, Inc.
    Full Title: A Phase 2 Dose Ranging, Randomized, Double Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of EDP-305 in Subjects with Primary Biliary Cholangitis...
    Medical condition: Primary Biliary Cholangitis (PBC)
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004871 10036680 Primary biliary cirrhosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) BE (Completed) ES (Completed) AT (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2013-001370-20 Sponsor Protocol Number: OPV116910 Start Date*: 2014-11-26
    Sponsor Name:Glaxo Group Ltd
    Full Title: OPV116910: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Investigate the Efficacy and Safety of Ofatumumab Injection for Subcutaneous Use in Subjects with Pemphigus Vulgaris
    Medical condition: Pemphigus Vulgaris
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004858 10052802 Pemphigus vulgaris LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended) HR (Completed) GR (Completed) PL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-002915-23 Sponsor Protocol Number: ARGX-113-1904 Start Date*: 2021-01-25
    Sponsor Name:argenx BV
    Full Title: A Randomized, Double-Blinded, Placebo-Controlled Trial to Investigate the Efficacy, Safety, and Tolerability of Efgartigimod PH20 SC in Adult Patients With Pemphigus (Vulgaris or Foliaceus) (ADDRESS)
    Medical condition: Pemphigus Vulgaris or Pemphigus Foliaceus
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10052802 Pemphigus vulgaris LLT
    20.0 100000004858 10057069 Pemphigus foliaceus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) FR (Completed) HU (Completed) BG (Completed) ES (Completed) GR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2021-004174-64 Sponsor Protocol Number: DMX-200-301 Start Date*: 2022-03-08
    Sponsor Name:Dimerix Bioscience Pty Ltd
    Full Title: A pivotal Phase 3, multicenter, randomized, double-blind, placebo-controlled study of the efficacy and safety of DMX-200 in patients with focal segmental glomerulosclerosis (FSGS) who are receiving...
    Medical condition: Focal segmental glomerulosclerosis
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038359 - Renal and urinary disorders 10067757 Focal segmental glomerulosclerosis PT
    21.1 10038359 - Renal and urinary disorders 10016832 Focal & segmental glomerulosclerosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Trial now transitioned) ES (Ongoing) FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2015-003564-37 Sponsor Protocol Number: PRN1008-005 Start Date*: 2016-04-21
    Sponsor Name:Principia Biopharma Australia Pty Ltd
    Full Title: An Open-Label, Phase 2, Pilot Study Investigating the Safety, Clinical Activity, Pharmacokinetics, and Pharmacodynamics of Oral Treatment with the BTK Inhibitor PRN1008 in Patients with Newly Diagn...
    Medical condition: Pemphigus: Pemphigus Vulgaris
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004858 10052802 Pemphigus vulgaris LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Completed) HR (Completed)
    Trial results: View results
    EudraCT Number: 2022-000060-22 Sponsor Protocol Number: 2020/0424/HP Start Date*: 2023-04-03
    Sponsor Name:CHU de Rouen
    Full Title: Comparison of a personalized maintenance therapy based on the evolution of anti-desmoglein antibodies as biomarkers of pemphigus subclinical activity, with the standard treatment (rituximab + corti...
    Medical condition: Pemphigus diseases (Pemphigus Vulgaris - PV and Pemphigus Foliaceus (PF).
    Disease: Version SOC Term Classification Code Term Level
    20.1 10015919 - Eye disorders 10067776 Ocular pemphigoid PT
    20.0 10040785 - Skin and subcutaneous tissue disorders 10034277 Pemphigoid PT
    21.1 10040785 - Skin and subcutaneous tissue disorders 10057052 Cicatricial pemphigoid LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-004666-26 Sponsor Protocol Number: 2015/208/HP Start Date*: 2017-07-19
    Sponsor Name:CHU-Hôpitaux de Rouen
    Full Title: Randomised double blind double dummy control trial comparing the safety and efficacy of rituximab versus oral cyclophosphamide in severe forms of mucous membrane pemphigoid
    Medical condition: severe forms of mucous membrane pemphigoid
    Disease: Version SOC Term Classification Code Term Level
    20.1 10015919 - Eye disorders 10067776 Ocular pemphigoid PT
    20.0 10040785 - Skin and subcutaneous tissue disorders 10034277 Pemphigoid PT
    21.1 10040785 - Skin and subcutaneous tissue disorders 10057052 Cicatricial pemphigoid LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-000713-32 Sponsor Protocol Number: CAEL101-302 Start Date*: 2021-02-09
    Sponsor Name:Caelum Biosciences, Inc.
    Full Title: A Phase 3, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of CAEL-101 and Plasma Cell Dyscrasia Treatment Versus Placebo and Plasma Cell Dyscrasia Treatment in Plasma Cell Dysc...
    Medical condition: stage IIIa cardiac AL amyloidosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10007541 - Cardiac disorders 10007509 Cardiac amyloidosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) DE (Trial now transitioned) GB (GB - no longer in EU/EEA) GR (Trial now transitioned) PL (Trial now transitioned) BE (Completed) IT (Trial now transitioned) AT (Trial now transitioned) CZ (Trial now transitioned) NL (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA